• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DPYD Gene Record

  • Summary
  • Interactions
  • Claims
  • DPYD 1806 Druggable GenomeClinically Actionable

    Alternate Names:

    1806
    DIHYDROPYRIMIDINE DEHYDROGENASE
    DPYD
    DHP
    DHPDHASE
    DPD
    612779
    3012
    ENSG00000188641
    OTTHUMG00000039683
    1526
    Q12882
    DIHYDROPYRIMIDINE DEHYDROGENASE [NADP+] PRECURSOR (EC 1.3.1.2) (DPD) (DHPDHASE) (DIHYDROURACIL DEHYDROGENASE) (DIHYDROTHYMINE DEHYDROGENASE). [SOURCE:UNIPROT/SWISSPROT;ACC:Q12882]
    PA145
    Dihydrothymine dehydrogenase
    T75890
    DYPD
    Dihydropyrimidine dehydrogenase [NADP(+)]

    Gene Info:

    Target Class Enzymes
    Target Subclass EC:1.3.1.2
    Human Readable Name DRUGGABLE GENOME
    Gene Biotype PROTEIN_CODING
    (7 More Sources)

    Gene Categories: Category Details

    DRUGGABLE GENOME
    CLINICALLY ACTIONABLE
    ENZYME

    Publications:

    Stepanova et al., 2005, [Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential]., Vopr Onkol
    Caudle et al., 2013, Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing., Clin. Pharmacol. Ther.
    Van Kuilenburg AB et al., 1997, Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity., Eur J Cancer
    Vreken P et al., 1997, Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W., Hum Genet
    Holopainen I et al., 1997, Partial epilepsy in a girl with a symptom-free sister: first two Finnish patients with dihydropyrimidine dehydrogenase deficiency., J Inherit Metab Dis
    O'Donnell PH et al., 2020, Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015., Breast Cancer Res Treat
    Lampropoulou DI et al., 2020, Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA?, J Oncol Pharm Pract
    Iachetta F et al., 2019, The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study., Br J Cancer
    Del Re M et al., 2019, DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients., Pharmacogenomics J
    Madi A et al., 2018, Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy., Eur J Cancer
    Tariq Z et al., 2018, Capecitabine Toxicity and Dihydropyrimidine Dehydrogenase Deficiency., Am J Ther
    Duley JA et al., 2018, Preliminary Evidence for Enhanced Thymine Absorption: A Putative New Phenotype Associated With Fluoropyrimidine Toxicity in Cancer Patients., Ther Drug Monit
    Nahid NA et al., 2018, DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer., Cancer Chemother Pharmacol
    Zurayk M et al., 2019, Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature., J Oncol Pharm Pract
    Henricks LM et al., 2018, Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency., Int J Cancer
    Nie Q et al., 2017, Quantitative Contribution of rs75017182 to Dihydropyrimidine Dehydrogenase mRNA Splicing and Enzyme Activity., Clin Pharmacol Ther
    Meulendijks D et al., 2017, Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies., Pharmacogenomics J
    Roberto M et al., 2017, Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine., Eur J Clin Pharmacol
    Milano G, 2016, Highlight on DPYD gene polymorphisms and treatment by capecitabine (.)., Scand J Clin Lab Invest Suppl
    González-Perera I et al., 2017, 5-fluorouracil toxicity in the treatment of colon cancer associated with the genetic polymorphism 2846 A>G (rs67376798)., J Oncol Pharm Pract
    Zhao XQ et al., 2016, DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia., Tumour Biol
    Kuilenburg ABPV et al., 2016, Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene., Biochim Biophys Acta
    Boige V et al., 2016, DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial., JAMA Oncol
    Meulendijks D et al., 2015, Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data., Lancet Oncol
    Thomas F et al., 2016, Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio., Clin Pharmacol Ther
    Gentile G et al., 2016, Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction., Pharmacogenomics J
    Toffoli G et al., 2015, Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines., Int J Cancer
    Dhelens C et al., 2016, Lethal 5-fluorouracil toxicity in a colorectal patient with severe dihydropyrimidine dehydrogenase (DPD) deficiency., Int J Colorectal Dis
    Joerger M et al., 2015, Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy., Cancer Chemother Pharmacol
    Sistonen J et al., 2014, Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio., Pharmacogenomics
    Froehlich TK et al., 2015, Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity., Int J Cancer
    Cai X et al., 2014, The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: a preliminary report., Eur Rev Med Pharmacol Sci
    Teh LK et al., 2013, Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients., Ther Drug Monit
    Terrazzino S et al., 2013, DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis., Pharmacogenomics
    Saif MW, 2013, Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD., Cancer Genomics Proteomics
    Magnani E et al., 2013, Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule., Intern Emerg Med
    Zhang XP et al., 2012, Polymorphisms of dihydropyrimidine dehydrogenase gene and clinical outcomes of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population., Chin Med J (Engl)
    Deenen MJ et al., 2011, Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer., Clin Cancer Res
    Obi EE et al., 2011, A bilateral cicatricial ectropion and bilateral upper lid shortening caused by 5-fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency., Cutan Ocul Toxicol
    Kristensen MH et al., 2010, Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients., J Int Med Res
    Fariña-Sarasqueta A et al., 2010, Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study., Cancer Chemother Pharmacol
    Boige V et al., 2010, Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05., J Clin Oncol
    Braun MS et al., 2009, Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial., J Clin Oncol
    Loganayagam A et al., 2010, The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients., Cancer Chemother Pharmacol
    Amstutz U et al., 2009, Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment., Pharmacogenomics
    Kleibl Z et al., 2009, Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy., Neoplasma
    van Kuilenburg AB et al., 2008, Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1G > A mutation in the dihydropyrimidine dehydrogenase gene., Nucleosides Nucleotides Nucleic Acids
    He YF et al., 2008, Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients., J Clin Pharm Ther
    Sulzyc-Bielicka V et al., 2008, 5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients., Pharmacol Rep
    Schwab M et al., 2008, Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group., J Clin Oncol
    Zhang H et al., 2007, DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients., Med Oncol
    Capitain O et al., 2008, The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer., Pharmacogenomics J
    Cho HJ et al., 2007, Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity., Ther Drug Monit
    Salgado J et al., 2007, Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer., Oncol Rep
    Saif MW et al., 2007, DPYD*2A mutation: the most common mutation associated with DPD deficiency., Cancer Chemother Pharmacol
    Morel A et al., 2006, Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance., Mol Cancer Ther
    Boisdron-Celle M et al., 2007, 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency., Cancer Lett
    Largillier R et al., 2006, Pharmacogenetics of capecitabine in advanced breast cancer patients., Clin Cancer Res
    Ezzeldin HH et al., 2005, Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients., Clin Cancer Res
    Al-Sanna'a NA et al., 2005, Dihydropyrimidine dehydrogenase deficiency presenting at birth., J Inherit Metab Dis
    Seck K et al., 2005, Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals., Clin Cancer Res
    Takechi T et al., 2005, Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts., Oncol Rep
    Hsiao HH et al., 2004, Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population., Cancer Chemother Pharmacol
    Salgueiro N et al., 2004, Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients., Genet Med
    Gross E et al., 2003, Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects., Hum Mutat
    Van Kuilenburg AB et al., 2002, High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity., Pharmacogenetics
    Van Kuilenburg AB et al., 2002, Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation., Int J Cancer
    Johnson MR et al., 2002, Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype., Clin Cancer Res
    Raida M et al., 2001, Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls., Clin Cancer Res
    van Kuilenburg AB et al., 2001, Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency., Clin Cancer Res
    van Kuilenburg AB et al., 2000, Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene., Clin Cancer Res
    Collie-Duguid ES et al., 2000, Known variant DPYD alleles do not explain DPD deficiency in cancer patients., Pharmacogenetics
    Van Kuilenburg AB et al., 1999, Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency., Hum Genet
    Cao et al., 1995, 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil., Cancer Res.
    Saif et al., 2006, Dihydropyrimidine dehydrogenase deficiency in an Indian population., Cancer Chemother. Pharmacol.
    Jakob et al., 2004, Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer., J. Pathol.
    Araki et al., 2001, Dihydropyrimidine dehydrogenase activity and thymidylate synthase level are associated with response to 5-fluorouracil in human colorectal cancer., Kurume Med J
    Hisamitsu et al., Expression of dihydropyrimidine dehydrogenase in cancer cells but not in stromal cells predicts the efficacy of fluorouracil treatment in patients with gastric carcinoma., Anticancer Res.
    Ciaparrone et al., 2006, Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil., Oncology
    Majounie E et al., 2020, Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic <i>DPYD</i> structural variant., Cold Spring Harb Mol Case Stud
    Boisdron-Celle M et al., 2017, A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification., Semin Oncol
    Ichikawa et al., 2003, Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer., Clin. Cancer Res.
    Ishida et al., 2002, [A case of liver metastasis of rectal cancer demonstrating complete response to 5-FU + Leucovorin + UFT]., Gan To Kagaku Ryoho
    Czito et al., 2006, A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract., Cancer Invest.
    Leichman et al., 2006, Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: characterization and exploratory analysis with survival., J Chemother
  • TEGAFUR   DPYD

    Interaction Score: 130.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9470816 9439663 9323575 32378051 31382864 30858516 30723313 30114658 29889674 29846282 29134491 28950804 28929491 28295243 27995989 27864592 27454530 27122156 26846104 26804652 26794347 26603945 26265035 26216193 26099996 25796495 25677447 25410891 24923815 24817302 23988873 23942539 23930673 23603345 23585145 22490566 21498394 21077799 20819423 20665215 20385995 19858398 19795123 19530960 19473056 18600527 18452418 18443386 18299612 17848752 17700593 17417073 17203168 17165084 17121937 17064846 17000685 16361556 16151913 16115930 15944764 15132136 15017333 14635116 12360106 12209976 11895907 11555601 11350878 11156223 10803677 10071185 8521418


    Sources:
    NCI CIViC PharmGKB

  • ENILURACIL   DPYD

    Interaction Score: 10.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name eniluracil
    Novel drug target Novel Target

    PMIDs:
    16466986


    Sources:
    TdgClinicalTrial TTD

  • GIMERACIL   DPYD

    Interaction Score: 6.87

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name S-1, TS1
    Novel drug target Novel Target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • FLUCYTOSINE   DPYD

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LEUCOVORIN   DPYD

    Interaction Score: 1.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12576451 11977552 31871216


    Sources:
    NCI CIViC PharmGKB

  • CAPECITABINE   DPYD

    Interaction Score: 0.95

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16279094 23988873


    Sources:
    NCI CIViC FDA

  • FLUOROURACIL   DPYD

    Interaction Score: 0.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16421754 15538739 11501504 15330204 17179731 31871216 23988873


    Sources:
    NCI CIViC TTD FDA

  • OXALIPLATIN   DPYD

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17127229


    Sources:
    NCI

  • IRINOTECAN   DPYD

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28395759


    Sources:
    PharmGKB

  • Ensembl: ENSG00000188641

    • Version: 101_38

    Alternate Names:
    DPYD Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TdgClinicalTrial: Q12882

    • Version: January-2014

    Alternate Names:
    DPYD Gene Symbol

    Gene Info:
    Target Class Enzymes
    Target Subclass EC:1.3.1.2

    Publications:

  • RussLampel: ENSG00000188641

    • Version: 26-July-2011

    Alternate Names:
    ENSG00000188641 Ensembl Gene Id
    DIHYDROPYRIMIDINE DEHYDROGENASE [NADP+] PRECURSOR (EC 1.3.1.2) (DPD) (DHPDHASE) (DIHYDROURACIL DEHYDROGENASE) (DIHYDROTHYMINE DEHYDROGENASE). [SOURCE:UNIPROT/SWISSPROT;ACC:Q12882] Description
    DPYD Display Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • PharmGKB: DPYD

    • Version: 18-August-2020

    Alternate Names:
    PA145 PharmGKB ID

    Gene Info:

    Publications:
    Van Kuilenburg AB et al., 2002, Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation., Int J Cancer
    Zurayk M et al., 2019, Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature., J Oncol Pharm Pract
    Froehlich TK et al., 2015, Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity., Int J Cancer

  • CIViC: DPYD

    • Version: 14-September-2020

    Alternate Names:
    1806 Entrez Gene ID
    1526 CIViC Gene ID

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:
    Caudle et al., 2013, Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing., Clin. Pharmacol. Ther.
    Majounie E et al., 2020, Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic <i>DPYD</i> structural variant., Cold Spring Harb Mol Case Stud

  • NCI: DPYD

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Ciaparrone et al., 2006, Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil., Oncology
    Araki et al., 2001, Dihydropyrimidine dehydrogenase activity and thymidylate synthase level are associated with response to 5-fluorouracil in human colorectal cancer., Kurume Med J
    Cao et al., 1995, 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil., Cancer Res.

  • HingoraniCasas: ENSG00000188641

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000188641 Gene Symbol
    DPYD Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • Tempus: DPYD

    • Version: 11-November-2018

    Alternate Names:
    DPYD Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • TTD: Dihydrothymine dehydrogenase

    • Version: 2020.06.01

    Alternate Names:
    DPYD TTD Gene Abbreviation
    T75890 TTD Target ID

    Gene Info:

    Publications:

  • Pharos: DPYD

    • Version: 01-February-2022

    Alternate Names:
    Dihydropyrimidine dehydrogenase [NADP(+)] Gene Name
    Q12882 UniProt ID

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

  • FDA: DPYD

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21